Baccouche, I.; Bensmail, D.; Leblong, E.; Fraudet, B.; Aymard, C.; Quintaine, V.; Pottier, S.; Lansaman, T.; Malot, C.; Gallien, P.;
et al. Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study. Toxins 2022, 14, 582.
https://doi.org/10.3390/toxins14090582
AMA Style
Baccouche I, Bensmail D, Leblong E, Fraudet B, Aymard C, Quintaine V, Pottier S, Lansaman T, Malot C, Gallien P,
et al. Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study. Toxins. 2022; 14(9):582.
https://doi.org/10.3390/toxins14090582
Chicago/Turabian Style
Baccouche, Ines, Djamel Bensmail, Emilie Leblong, Bastien Fraudet, Claire Aymard, Victorine Quintaine, Sandra Pottier, Thibaud Lansaman, Claire Malot, Philippe Gallien,
and et al. 2022. "Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study" Toxins 14, no. 9: 582.
https://doi.org/10.3390/toxins14090582
APA Style
Baccouche, I., Bensmail, D., Leblong, E., Fraudet, B., Aymard, C., Quintaine, V., Pottier, S., Lansaman, T., Malot, C., Gallien, P., & Levy, J.
(2022). Goal-Setting in Multiple Sclerosis-Related Spasticity Treated with Botulinum Toxin: The GASEPTOX Study. Toxins, 14(9), 582.
https://doi.org/10.3390/toxins14090582
